Postoperative Tolvaptan Use in Left Ventricular Assist Device Implantation Patients

Plain-language summary

This study evaluates the use of the drug Tolvaptan after surgery in patients with advanced heart failure who receive a left ventricular assist device. It included patients aged 18 and older who were scheduled for device implantation. The study had no assigned phase and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Completed

Sponsor

University of Chicago

Intervention

tolvaptan

Start date

3/28/2019

Estimated completion

5/1/2022

Countries

United States

Related genes

Locations

• Chicago, United States

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Hospitalized patients with American College of Cardiology (ACC) and the American Heart Association (AHA) Stage D heart failure and plan to undergo LVAD implantation
* Age greater than or equal to 18 years old

Exclusion Criteria:

* No plan for LVAD implantation
* Age less than 18 years old